Bionova was founded by a team of scientists who saw a better way to deliver biologics process development and process characterization services. They were committed to building a business that clients could trust and rely upon. They also wanted to attract great scientific talent, give them great tools to work with, and build a workplace where people were empowered and energized to do great work and to share mutual respect for each other. They had spent time at big companies and were committed to not let meetings and bureaucracy slow them down.
Since those early days, Bionova has been on a transformative journey. Thanks to the contributions of our growing team of customer-focused specialists, we are now a full-service biologics CDMO and is constructing a state-of-the-art commercial-ready GMP manufacturing facility. With the support of its private equity partner, Great Point Partners, Bionova is currently working towards launch of GMP operations in 2021. The company has already announced multiple GMP clinical supply contracts, despite the months of construction and commissioning that remain, a strong indicator of the trust that clients feel toward Bionova.
A major priority for Bionova’s leadership team continues to be nurturing a culture focused on caring for the best interest of the client’s programs while also ensuring scientific excellence. The flexible, boutique-like environment allows the Bionova team to make each client a priority. This client-first approach has enabled the company to cultivate a network of clients loyal to Bionova, resulting continued growth.